androgen receptor regulated long noncoding RNA 1Genealiases: LINC02170 · PRCAT47
Q-omics provides the consensus-scored ARLNC1 profile across patient tissues and cancer cell-line models. ARLNC1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARLNC1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ARLNC1 RNA expression shows 14,737 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where ARLNC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARLNC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARLNC1 survival associations across molecular data types. ARLNC1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARLNC1 RNA expression–survival associations across cancer types. High ARLNC1 expression shows unfavorable associations in MESO, ACC, LGG and BRCA, but favorable associations in BLCA and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for ARLNC1 RNA expression.
This table summarizes ARLNC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARLNC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARLNC1 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in LUSC, HNSC and PRAD. The THCA box plot shows higher ARLNC1 RNA expression in normal versus tumor tissue (log2 FC = −0.186, t-test p < 0.001).
This table shows molecular features associated with ARLNC1 in patient tissues and cancer cell lines. In patient samples, ARLNC1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
